Skip to main content
OpenTrials
Completed

NCT Number: NCT04091334

Monitoring Patients With Shortness of Breath With Repeated Ultrasound Examinations

Purpose of the study: The purpose of the trial is to investigate whether repeated ultrasound scans of the heart and lungs of patients with shortness of breath may help to optimize their treatment. This patient group is characterized by an extended hospitalization and a high mortality rate. Therefore, it is essential to be able to target the treatment in order to shorten length of stay, prevent readmissions, and improve survival in these patients. Ultrasound scanning used in this way is novel.

The study method: Initially, all patients will receive standard evaluation and ultrasound of the heart and the lungs. Then the patients are randomly assigned into two groups. In one group, patients receive standard assessment and treatment. In the second group, the patients, in addition to standard examination and treatment, receive ultrasound scans of their heart and lungs after two hours and again fire hours after the first scan.

After discharge, the subjects are followed for one year to evaluate what examinations and treatment they received during hospitalization, whether they have been readmitted or died.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Emergency Medicine, Slagelse, Region Sjælland, Denmark

Loading trial locations.

About this study

Design: Multicenter, randomized, controlled, open-label, and pragmatic trial.

Settings: Several different emergency departments (EDs) in Denmark.

Study flow: After arrival, the patients are screened according to eligibility criteria. If patients meet the inclusion criteria and informed consent is obtained, the patients are randomly assigned to one of two groups. In both groups, the patients received standard evaluation, e.g., blood samples, physical examination, arterial blood gas, and in addition ultrasound examination of the heart and the lungs. In the intervention group, the patients are further examined with serial ultrasound scans of the heart and the lungs after two and four hours after the initial evaluation.

In the course of admittance, the patients will have there baseline characteristics recorded together with the ultrasound findings, symptoms, and vitals. Symptoms will be recorded at a verbal dyspnea symptom scale (VDS) from 0-10.

All data will be registered at the same time points to make comparisons: At 1, 2, 4 and after 5 hours.

Sample size: This is calculated from the primary outcome and with an assumption of a power of 80%, type 1-error of 5%, and 10% dropouts. The calculations are based on previous studies using the VDS on patients with acute dyspnea. The sample size is 103 patients in each group.

Statistical analysis: Baseline characteristics will be summarized and divided into the intervention and control group. Continuous variables will be summarized as means and standard deviation (SD) or medians and interquartile range (IQR) depending on the distribution of the variable. For categorical variables, frequencies and percentages will be reported.

The primary outcome - change in dyspnea on VDS - will be compared between the two groups to detect any difference. Pairwise comparisons of VDS will be made at the same time points in both groups.

The secondary outcomes: Length of stay, death, and the number of readmissions will be compared between the two groups to detect a difference. Time-to-event (dead or readmission) will be visualized with Kaplan Meier curves.

In the case of lost to follow-up or other reasons for missing data both intention-to-treat and per-protocol analysis will be used.

The secondary outcomes in the interventions group: The dynamic changes in inferior vena cava collapsibility index (IVC-CI) and the sum of B-lines will be expressed as means and SD or median and IQR depending on the distribution of the data and compared between the different time points. Furthermore, IVC-CI and the sum of B-lines will be compared to vitals and VDS-score to detect a correlation.

The inter- and intraobserver variability regarding the focused ultrasound will be accessed.

Data management: The registered data on each patient will be recorded and securely stored in an encrypted, logged, and password-protected database called REDCap. All adjustments in the database are logged. The patients are anonymized.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants should be 18 years or older
  • Presented at the ED with shortness of breath (asking the patient upon arrival in the triage what their primary complaint is for a referral to an emergency department)
  • Written informed consent obtained from the patient

Exclusion criteria

  • Patients with dyspnea primary admitted because of a trauma

Treatment and study plan

Focused ultrasound of the lungs (FLUS) and focused cardiac ultrasound (FoCUS)

Device

FLUS: Scanning 8 zones of the front and lateral of the thorax. Record number of B-lines, consolidations, pneumothorax, pleural effusions.

FoCUS: Scan the heart in different views and record the ejection fraction, size of the right side of the heart, pericardial effusion, tricuspid annular plane systolic excursion (TAPSE), inferior vena cava (IVC) diameter, and IVC collapsibility Index (IVC-CI).

Standard care

Other

Standard care and evaluation and monitoring

Primary outcomes

  1. Change in dyspnea severity on a verbal dyspnea scale (VDS) from 0-10

    Time frame: Assessed within 1 hour from arrival, again after two, four hours and five hours

    Self reported severity of dyspnea. 0 = no dyspnea. 10 = worst dyspnea ever.

Secondary outcomes

  1. Lenght of stay

    Time frame: Assessed after 30 days from inclusion of the last patient.

    Number of days the patients is admitted.

  2. Number of readmission(s)

    Time frame: Assessed up to 12 months from inclusion of the last patient.

    Number of times the patients is readmitted after discharge.

  3. In-hospital all-cause mortality

    Time frame: Assessed after 30 days from inclusion of the last patient.

    Number of patients who dies under the admission

  4. All-cause mortality after discharge

    Time frame: Assessed up to 12 months from inclusion of the last patient.

    Number of patients who dies after discharge.

  5. IVC-CI (inferior vena cava collapsibility index) correlated to vital signs and VDS

    Time frame: Assessed within 1 hour from arrival, again after two, four hours and five hours

  6. B-line count correlated to vital signs and VDS

    Time frame: Assessed within 1 hour from arrival, again after two, four hours and five hours

  7. The changes in IVC-CI between the ultrasound examinations

    Time frame: Assessed within 1 hour from arrival, again after two, four hours and five hours

  8. The changes in B-line count between the ultrasound examinations

    Time frame: Assessed within 1 hour from arrival, again after two, four hours and five hours

Sponsors and collaborators

Lead sponsor

Slagelse Hospital

Other

Collaborators

  • Herning Hospital
  • Holbaek Sygehus
  • Horsens Hospital
  • Hvidovre University Hospital
  • Odense University Hospital
  • Zealand University Hospital

Registry information

Official study title

Monitoring Patients With Acute Dyspnea With Serial Focused Ultrasound of the Heart and the Lungs

Acronym: MODUS

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
Sep 16, 2019
Registry last updated
Oct 6, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.